Adoptive T cell immunotherapy of human uveal melanoma targeting gp100

Journal of Immunology

Volumn 165, Issue 12, 2000, Pages 7308-7315

  Sutmuller, R P M ^a   Schurmans, L R H M ^a   Van Duivenvoorde, L M ^a   Tine, J A ^a   Van der Voort, E I H ^a   Toes, R E M ^a   Melief, C J M ^a   Jager, M J ^a   Offringa, R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 100; HLA A ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTERIOR EYE CHAMBER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ISOLATION; CELL SUSPENSION; CHIMERA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; IMMUNOCOMPETENCE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; TRANSGENIC MOUSE; UVEA MELANOMA; VIRUS RECOMBINANT; XENOGRAFT;

EID: 0034672071     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.12.7308     Document Type: Article

References (52)

1. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups
2. Human CTL epitopes encoded by human pepillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides
3. Targeting p53 as a general tumor antigen
4. Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA)
5. Identification of HLA-A*0201 -restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product
6. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2 1 and human CD 8
7. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas
8. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice
9. Generation of human T-cell responses to an HLA-A2 1-restricted peptide epitope derived from α-fetoprotein
10. Recombinant virus vaccination against 'self' antigens using anchorfixed immunogens
11. Targeting p53 for adoptive T-cell immunotherapy
12. Redirecting effector T cells through their IL-2 receptors
13. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class 1 major histocompatibility complex
14. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma
15. The treatment of metastatic uveal melanoma
16. Infrequent expression of the MAGE gene family in uveal melanomas
17. Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines
18. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma
19. Immune deviation in relation to ocular immune privilege
20. A vision of cell death insights into immune privilege
21. Melanomas that develop within the eye inhibit lymphocyte proliferation
22. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2 1-restricted anti-melanoma CTL line
23. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes possible mechanisms for immunotherapeutic failures
24. Establishment and characterization of an uveal-melanoma cell line
25. The specificity of the microcytotoxicity assay for cell-mediated immunity in human bladder cancer
26. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene
27. Protective anti-tumor Immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion
28. Successful immunotherapy of an Intraocular tumor in mice
29. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic
30. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
31. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection
32. An HLA-A2 polyepitope vaccine for melanoma immunotherapy
33. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy
34. Human leukocyte antigen class I expression marker of poor prognosis in uveal melanoma
35. HLA expression and tumor-infiltrating immune cells in uveal melanoma
36. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8
37. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy
38. Generation of tumor-specific T lymphocytes for the treatment of posttransplant lymphoma
39. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases In SCID/hu mice
40. Immunotherapy with effector cells and 1L-2 of lymph node metastases of human squamous-cell carcinoma of the head and neck established in nude mice
41. Inhibition of the growth of human melanoma xenografts in nude mice by human tumor-specific cytotoxic T-cells
42. An autologous T cell clone overcomes Intra-melanoma heterogeneity for susceptibility to cell-mediated lysis by using multiple lytic mechanisms in vitro and in vivo analysis
43. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma
44. Intracamerally induced concomitant Immunity mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge
45. Regulation of the proinflammatory effects of Fas ligand (CD95L)
46. T cell immunity induced by allogeneic microglia in relation to neuronal retina transplantation
47. Immunoselection in vivo independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
48. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
49. Immune selection after antigen-specific immunotherapy of melanoma Surgery
50. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes
51. Importance of MHC class 1 α2 and α3 domains in the recognition of self and nonself MHC molecules
52. Suppressed cellular immunity in mice harboring intraocular melanomas